Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 8/20 | 0.46 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20767162 | 0.82 | NPC1 (0.49) | — | |
| SCHEMBL20767328 | 0.77 | RAB9A (0.53) | — | |
| SCHEMBL20766814 | 0.77 | HDAC1 (0.53) | HDAC1HDAC3HDAC2NCOR2NCOR1 | |
| SCHEMBL16926480 | 0.73 | NPC1 (0.55) | — | |
| SCHEMBL23992177 | 0.73 | HDAC1 (0.62) | HDAC1HDAC3HDAC2NCOR2NCOR1 | |
| SCHEMBL20767264 | 0.70 | IDO1 (0.59) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL16886014 | 0.69 | HDAC1 (0.82) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL1266865 | 0.69 | HDAC1 (0.68) | HDAC1HDAC3HDAC2NCOR2NCOR1 | |
| SCHEMBL15551664 | 0.68 | HDAC1 (1.00) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL18086518 | 0.68 | HDAC3 (0.67) | HDAC1HDAC3HDAC2NCOR2NCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3672970-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-111051305-A | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | HDAC1 207/4885HDAC3 198/4885HDAC2 428/4885 |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | HDAC1 207/4885HDAC3 198/4885HDAC2 428/4885 |
| US-11040033-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | HDAC1 207/4885HDAC3 198/4885HDAC2 428/4885 |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | SDHA, CYP11B2, ABCB1 | HDAC1 207/4885HDAC3 198/4885HDAC2 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.